Jingyu An , Roma Kurilov , Teresa Peccerella , Frank Bergmann , Mouad Edderkaoui , Adrian Lim , Xu Zhou , Katrin Pfütze , Angela Schulz , Stephan Wolf , Kai Hu , Christoph Springfeld , Sadaf S. Mughal , Lenart Zezlina , Franco Fortunato , Georg Beyer , Julia Mayerle , Susanne Roth , Johannes Hulkkonen , Daniela Merz , John P. Neoptolemos
{"title":"Metavert 在人 PDAC 有机体中与标准细胞毒性药物协同作用，并与治疗反应的转录组特征相关联","authors":"Jingyu An , Roma Kurilov , Teresa Peccerella , Frank Bergmann , Mouad Edderkaoui , Adrian Lim , Xu Zhou , Katrin Pfütze , Angela Schulz , Stephan Wolf , Kai Hu , Christoph Springfeld , Sadaf S. Mughal , Lenart Zezlina , Franco Fortunato , Georg Beyer , Julia Mayerle , Susanne Roth , Johannes Hulkkonen , Daniela Merz , John P. Neoptolemos","doi":"10.1016/j.tranon.2024.102109","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Despite some recent advances, pancreatic ductal adenocarcinoma (PDAC) remains a growing oncological challenge. New drugs capable of targeting more than one oncogenic pathway may be one way to improve patient outcomes. This study characterizes the effectiveness of Metavert a first-in-class dual inhibitor of GSK3-β and histone deacetylase in treating PDAC as a single agent or in combination with standard cytotoxics.</p></div><div><h3>Methods</h3><p>Thirty-six Patient-Derived Organoids (hPDOs) characterised by RNASeq and whole exome sequencing were treated with Metavert alone or in combination with standard cytotoxics. Transcriptomic signatures (TS) representing sensitivity to Metavert alone or sensitivity to Metavert + irinotecan (IR) were evaluated in 47 patient samples, chemo-naïve in 26 and post-chemotherapy in 21 (gemcitabine=5; FOLFIRINOX=14, both=2) with companion multiplexed immunofluorescence and RNASeq data.</p></div><div><h3>Results</h3><p>Metavert combined with gemcitabine, irinotecan, 5FU, oxaliplatin, and paclitaxel was synergistic in the hPDOs. Basal-subtype hPDOs were more sensitive to Metavert alone whereas the Metavert+IR combination exhibited synergy in Classical-subtype hPDOs with increased apoptosis and autophagy. hPDO-derived TS evaluated in PDAC tissues demonstrated that Metavert-TS<sup>Hi</sup> samples were enriched for mRNA splicing and DNA repair processes; they were associated with Basal-like tissues but also with GATA6<sup>+ve</sup>-chemo-naïve samples and were higher following gemcitabine but not FOLFIRINOX treatment. In contrast, Metavert+IR-TS<sup>HI</sup> samples were enriched for TP53 pathways; they were associated with Classical-like pretreatment samples and with GATA6<sup>+ve</sup>/KRT17<sup>+ve</sup> hybrid cell types following FOLFIRINOX, but not gemcitabine treatment, and were unrelated to transcriptional subtypes.</p></div><div><h3>Conclusions</h3><p>Metavert as a single agent and in combination with irinotecan offers novel strategies for treating pancreatic cancer.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"49 ","pages":"Article 102109"},"PeriodicalIF":5.0000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523324002365/pdfft?md5=f85533617deafcbac6264f8bce5bbb23&pid=1-s2.0-S1936523324002365-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response\",\"authors\":\"Jingyu An , Roma Kurilov , Teresa Peccerella , Frank Bergmann , Mouad Edderkaoui , Adrian Lim , Xu Zhou , Katrin Pfütze , Angela Schulz , Stephan Wolf , Kai Hu , Christoph Springfeld , Sadaf S. Mughal , Lenart Zezlina , Franco Fortunato , Georg Beyer , Julia Mayerle , Susanne Roth , Johannes Hulkkonen , Daniela Merz , John P. Neoptolemos\",\"doi\":\"10.1016/j.tranon.2024.102109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Despite some recent advances, pancreatic ductal adenocarcinoma (PDAC) remains a growing oncological challenge. New drugs capable of targeting more than one oncogenic pathway may be one way to improve patient outcomes. This study characterizes the effectiveness of Metavert a first-in-class dual inhibitor of GSK3-β and histone deacetylase in treating PDAC as a single agent or in combination with standard cytotoxics.</p></div><div><h3>Methods</h3><p>Thirty-six Patient-Derived Organoids (hPDOs) characterised by RNASeq and whole exome sequencing were treated with Metavert alone or in combination with standard cytotoxics. Transcriptomic signatures (TS) representing sensitivity to Metavert alone or sensitivity to Metavert + irinotecan (IR) were evaluated in 47 patient samples, chemo-naïve in 26 and post-chemotherapy in 21 (gemcitabine=5; FOLFIRINOX=14, both=2) with companion multiplexed immunofluorescence and RNASeq data.</p></div><div><h3>Results</h3><p>Metavert combined with gemcitabine, irinotecan, 5FU, oxaliplatin, and paclitaxel was synergistic in the hPDOs. Basal-subtype hPDOs were more sensitive to Metavert alone whereas the Metavert+IR combination exhibited synergy in Classical-subtype hPDOs with increased apoptosis and autophagy. hPDO-derived TS evaluated in PDAC tissues demonstrated that Metavert-TS<sup>Hi</sup> samples were enriched for mRNA splicing and DNA repair processes; they were associated with Basal-like tissues but also with GATA6<sup>+ve</sup>-chemo-naïve samples and were higher following gemcitabine but not FOLFIRINOX treatment. In contrast, Metavert+IR-TS<sup>HI</sup> samples were enriched for TP53 pathways; they were associated with Classical-like pretreatment samples and with GATA6<sup>+ve</sup>/KRT17<sup>+ve</sup> hybrid cell types following FOLFIRINOX, but not gemcitabine treatment, and were unrelated to transcriptional subtypes.</p></div><div><h3>Conclusions</h3><p>Metavert as a single agent and in combination with irinotecan offers novel strategies for treating pancreatic cancer.</p></div>\",\"PeriodicalId\":48975,\"journal\":{\"name\":\"Translational Oncology\",\"volume\":\"49 \",\"pages\":\"Article 102109\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2024-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1936523324002365/pdfft?md5=f85533617deafcbac6264f8bce5bbb23&pid=1-s2.0-S1936523324002365-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1936523324002365\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523324002365","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response
Background
Despite some recent advances, pancreatic ductal adenocarcinoma (PDAC) remains a growing oncological challenge. New drugs capable of targeting more than one oncogenic pathway may be one way to improve patient outcomes. This study characterizes the effectiveness of Metavert a first-in-class dual inhibitor of GSK3-β and histone deacetylase in treating PDAC as a single agent or in combination with standard cytotoxics.
Methods
Thirty-six Patient-Derived Organoids (hPDOs) characterised by RNASeq and whole exome sequencing were treated with Metavert alone or in combination with standard cytotoxics. Transcriptomic signatures (TS) representing sensitivity to Metavert alone or sensitivity to Metavert + irinotecan (IR) were evaluated in 47 patient samples, chemo-naïve in 26 and post-chemotherapy in 21 (gemcitabine=5; FOLFIRINOX=14, both=2) with companion multiplexed immunofluorescence and RNASeq data.
Results
Metavert combined with gemcitabine, irinotecan, 5FU, oxaliplatin, and paclitaxel was synergistic in the hPDOs. Basal-subtype hPDOs were more sensitive to Metavert alone whereas the Metavert+IR combination exhibited synergy in Classical-subtype hPDOs with increased apoptosis and autophagy. hPDO-derived TS evaluated in PDAC tissues demonstrated that Metavert-TSHi samples were enriched for mRNA splicing and DNA repair processes; they were associated with Basal-like tissues but also with GATA6+ve-chemo-naïve samples and were higher following gemcitabine but not FOLFIRINOX treatment. In contrast, Metavert+IR-TSHI samples were enriched for TP53 pathways; they were associated with Classical-like pretreatment samples and with GATA6+ve/KRT17+ve hybrid cell types following FOLFIRINOX, but not gemcitabine treatment, and were unrelated to transcriptional subtypes.
Conclusions
Metavert as a single agent and in combination with irinotecan offers novel strategies for treating pancreatic cancer.
期刊介绍：
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
